From: LATE-NC aggravates GVD-mediated necroptosis in Alzheimer’s disease
Variable | Frequency | Mean | |
---|---|---|---|
Age | – | 67 years (range 25–96 years) | |
Male/Female | 127 (55%)/ 103 (45%) | Not applicable | |
Neuropathological diagnosis | Non-ADNC | 82 (37%) | Not applicable |
p-preAD | 81 (36%) | ||
Demented ADNC | 67 (27%) | ||
Cognition | Non-impaired | 83 (47%) | Not applicable |
Dementia | 95 (53%) | ||
Not available | 52 | ||
Braak NFT Stage | 0 | 40 (17%) | II |
I | 68 (30%) | ||
II | 36 (16%) | ||
III | 19 (8%) | ||
IV | 25 (11%) | ||
V | 20 (9%) | ||
VI | 22 (9%) | ||
AβMTL Phase | 0 | 87 (38%) | 2 |
1 | 20 (9%) | ||
2 | 20 (9%) | ||
3 | 29 (12%) | ||
4 | 74 (32%) | ||
LATE-NC Stage | 0 | 132 (58%) | 1 |
1 | 10 (4%) | ||
2 | 62 (27%) | ||
3 | 26 (11%) | ||
GVD Stage | 0 | 112 (51%) | 1 |
1 | 39 (18%) | ||
2 | 12 (5%) | ||
3 | 12 (5%) | ||
4 | 28 (13%) | ||
5 | 18 (8%) | ||
CDR Score | 0 | 83 (47%) | 1 |
0.5 | 8 (4%) | ||
1 | 22 (12%) | ||
2 | 19 (11%) | ||
3 | 46 (26%) | ||
Not available | 52 | ||
CERAD Score | 0 | 149 (65%) | 1 |
1 | 21 (9%) | ||
2 | 34 (15%) | ||
3 | 26 (11%) | ||
APOE status | 2/2 | 1 (1%) | Not applicable |
2/3 | 14 (10%) | ||
3/3 | 73 (53%) | ||
3/4 | 40 (29%) | ||
4/4 | 10 (7%) | ||
Not available | 91 |